Modulation of anxiety by cortical serotonin 1A receptors. 2015

Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
Mouse Biology Unit, European Molecular Biology Laboratory Monterotondo, Italy.

Serotonin (5-HT) plays an important role in the modulation of behavior across animal species. The serotonin 1A receptor (Htr1a) is an inhibitory G-protein coupled receptor that is expressed both on serotonin and non-serotonin neurons in mammals. Mice lacking Htr1a show increased anxiety behavior suggesting that its activation by serotonin has an anxiolytic effect. This outcome can be mediated by either Htr1a population present on serotonin (auto-receptor) or non-serotonin neurons (hetero-receptor), or both. In addition, both transgenic and pharmacological studies have shown that serotonin acts on Htr1a during development to modulate anxiety in adulthood, demonstrating a function for this receptor in the maturation of anxiety circuits in the brain. However, previous studies have been equivocal about which Htr1a population modulates anxiety behavior, with some studies showing a role of Htr1a hetero-receptor and others implicating the auto-receptor. In particular, cell-type specific rescue and suppression of Htr1a expression in either forebrain principal neurons or brainstem serotonin neurons reached opposite conclusions about the role of the two populations in the anxiety phenotype of the knockout. One interpretation of these apparently contradictory findings is that the modulating role of these two populations depends on each other. Here we use a novel Cre-dependent inducible allele of Htr1a in mice to show that expression of Htr1a in cortical principal neurons is sufficient to modulate anxiety. Together with previous findings, these results support a hetero/auto-receptor interaction model for Htr1a function in anxiety.

UI MeSH Term Description Entries

Related Publications

Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
October 1998, FEBS letters,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
February 2012, Proceedings of the National Academy of Sciences of the United States of America,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
October 2004, Brain research. Molecular brain research,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
January 2019, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
December 2000, Metabolic brain disease,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
August 2004, The American journal of psychiatry,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
January 1987, Neurochemistry international,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
October 2009, Biological psychiatry,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
February 2022, Neuropharmacology,
Lukasz Piszczek, and Agnieszka Piszczek, and Joanna Kuczmanska, and Enrica Audero, and Cornelius T Gross
December 2018, Journal of psychopharmacology (Oxford, England),
Copied contents to your clipboard!